Roche's pharma sales up by 7%
This article was originally published in Scrip
Roche said strong demand for its HER2 breast-cancer franchise, plus Avastin and Actemra/RoActemra, led to a 7% increase in pharmaceuticals sales for the first nine months of 2013. US sales grew by 12%.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.